Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dr. Reddy's Laboratories Ltd ADR (NY: RDY ) 83.47 +1.20 (+1.46%) Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Dr. Reddy's Laboratories Ltd ADR < Previous 1 2 3 4 Next > Organon Stock Sees Relative Strength Rating Rise To 91 August 27, 2024 On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. Via Investor's Business Daily Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal August 24, 2024 Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... Via Talk Markets Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold August 20, 2024 On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. Via Investor's Business Daily Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? July 01, 2024 DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why. Via Chartmill Dr. Reddy's Labs Stock Sees Improved Technical Strength June 28, 2024 On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. Via Investor's Business Daily Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M June 26, 2024 Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth... Via Benzinga Dr Reddy's Laboratories: Q3 Earnings Insights January 30, 2024 Via Benzinga Is NYSE:RDY suited for quality investing? September 14, 2023 Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. Via Chartmill Should you consider NYSE:RDY for quality investing? August 21, 2023 DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. Via Chartmill India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. June 03, 2024 Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections. Via Investor's Business Daily RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 May 07, 2024 RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. Via InvestorPlace Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand February 22, 2024 Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. October 24, 2023 Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors. Via Chartmill Top 5 Health Care Stocks That May Fall Off A Cliff August 23, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Chart Of The Day: What's Cooking At Dr. Reddy's Lab July 28, 2023 100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha Via Talk Markets Intercept Settles Ocaliva Litigation With Reddy's Lab August 17, 2022 Via Benzinga Why Are Journey Medical Shares Trading Lower Today? July 11, 2023 Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release... Via Benzinga Why Are Journey Medical Shares Trading Higher Today June 13, 2023 Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the Via Benzinga The 3 Most Undervalued Value Stocks to Buy in June 2023 June 04, 2023 One positive aspect about broader market challenges is the rising opportunity in the best undervalued value stocks for June. Via InvestorPlace Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC May 13, 2023 Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... Via Talk Markets Why Aditxt Shares Are Surging Today April 20, 2023 Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases. Via Benzinga Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development March 23, 2023 Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development Via News Direct Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development March 22, 2023 Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. Via Benzinga Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 March 21, 2023 Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302 Via News Direct Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 March 20, 2023 Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. Via Benzinga Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal February 27, 2023 Via Benzinga The 3 Most Undervalued Stocks in India for Your February Buy List January 31, 2023 These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years. Via InvestorPlace Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years January 25, 2023 Intercept entered a deal with Amneal, likely lining up a series of new settlements. Via Investor's Business Daily Journey Medical Touts Positive PK Data For Bacterial Infection Candidate December 20, 2022 Via Benzinga Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug October 14, 2022 The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.